

Application No.	10/569,583
Amendment Dated	12 January 2007
Reply to Office Action of	12 December 2006

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Cancelled)
2. (Original) A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, and a bisphosphonate.
- 3-8. (Cancelled)
9. (Previously Presented) A combination according to claim 2 wherein the bisphosphonate is selected from tiludronic acid, ibandronic acid, incadronic acid, risedronic acid, zoledronic acid, clodronic acid, neridronic acid, pamidronic acid, alendronic acid, minodronic acid, olpadronic acid, TRK 530, CGP 47072, calcium clodronate or EB 1053.
10. (Cancelled)
11. (Currently amended) A pharmaceutical composition which comprises a combination as claimed in claim [[1]] 2 in association with a pharmaceutically acceptable diluent or carrier.
- 12-23. (Cancelled)
24. (New) A combination as claimed in claim 2, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and risedronic acid, or a pharmaceutically acceptable salt thereof.
25. (New) A combination as claimed in claim 2, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and zoledronic acid, or a pharmaceutically acceptable salt thereof.

Application No.	10/569,583
Amendment Dated	12 January 2007
Reply to Office Action of	12 December 2006

26. (New) A combination as claimed in claim 2, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and clodronic acid, or a pharmaceutically acceptable salt thereof.

27. (New) A combination as claimed in claim 2, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and pamidronic acid, or a pharmaceutically acceptable salt thereof.

28. (New) A combination as claimed in claim 2, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and alendronic acid, or a pharmaceutically acceptable salt thereof.